Bronchiolitis Obliterans Syndrome Market Growth Is Reshaping Competitive Advantage Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Bronchiolitis Obliterans Syndrome Market Revenue Growth Supported By A CAGR Of 2.42% Through 2030
The bronchiolitis obliterans syndrome market has experienced significant expansion in recent years. Its value is projected to rise from $1.59 billion in 2025 to $1.73 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.1%. This historical growth has been driven by factors such as the increase in organ transplant procedures, higher incidences of chronic graft rejection, advancements in hospital-based pulmonary care, the use of immunosuppressants, and limited early diagnostic capabilities.
The market size for bronchiolitis obliterans syndrome is anticipated to experience robust expansion over the coming years, reaching $2.43 billion by 2030 with a compound annual growth rate (CAGR) of 8.7%. This projected increase in the forecast period is driven by factors such as the growing number of transplant procedures, advancements in early detection technologies, the rise of personalized immunotherapy, the establishment of specialized respiratory centers, and improved long-term patient management strategies. Key trends shaping this period include heightened monitoring after transplantation, the expansion of immunosuppressive therapies, broader adoption of early diagnostic testing, a stronger emphasis on preserving long-term lung function, and an increasing demand for specialized pulmonary care services.
Download A Free Sample Report For Comprehensive Market Insights:
Bronchiolitis Obliterans Syndrome Market Opportunity Drivers: What Is Creating New Revenue Potential?
The anticipated rise in lung transplant procedures is set to drive the bronchiolitis obliterans syndrome market forward. Lung transplantation involves surgically replacing a diseased or failing lung with a healthy donor lung to enhance respiratory function. This procedure is becoming more common due to improvements in surgical methods, which have notably boosted success rates and lowered complication risks, making it safer and more attainable for patients requiring it. For advanced bronchiolitis obliterans syndrome, lung transplantation offers effective treatment by substituting damaged lungs with healthy ones, thereby improving respiration and lung capacity. Data from January 2025, provided by the Organ Procurement and Transplantation Network—a US-based non-profit scientific and educational organization—shows that lung transplants experienced the largest proportional increase, rising from 3,026 in 2023 to 3,340 in 2024, marking a 10.4 percent growth. Consequently, the increasing volume of lung transplants is fueling the expansion of the bronchiolitis obliterans syndrome market.
The growth of the bronchiolitis obliterans syndrome market is being propelled by a rise in clinical trials. These trials are research investigations conducted with human participants to assess the safety, efficacy, and effectiveness of medical interventions like drugs, devices, procedures, or behavioral therapies. Their increasing frequency stems from a growing demand for personalized medicine, which necessitates more studies to validate targeted, gene-based treatments. Clinical trials advance bronchiolitis obliterans syndrome care by evaluating novel therapies aimed at reducing inflammation and preserving lung function, while also improving knowledge of disease progression and treatment safety. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade organization, reported that industry-initiated clinical trials in the UK rose from 411 in 2022 to 426 in 2023, driven by a 16.5% uptick in Phase III trials. Thus, the uptrend in clinical trials is driving the bronchiolitis obliterans syndrome market forward.
Bronchiolitis Obliterans Syndrome Market Segment Landscape: Which Areas Lead Market Development?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
Bronchiolitis Obliterans Syndrome Market Innovation Trends Driving Future Development
Major players in the bronchiolitis obliterans syndrome market are prioritizing the development of innovative approaches like at-home nebulized therapy, which aims to boost medication adherence and decelerate disease progression by providing targeted, uninterrupted treatment. This therapy involves a nebulizer that converts liquid medicine into an inhalable mist, ensuring direct lung delivery. Its convenient, self-administered nature allows patients to effectively oversee respiratory health from their own homes. For example, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, introduced ARINA-1, which was granted Fast Track Designation by the Food and Drug Administration (FDA) for its role in halting the advancement of bronchiolitis obliterans syndrome (BOS) in individuals with bilateral lung transplants. This regulatory achievement highlights ARINA-1’s promise in addressing a significant gap in transplant care. The Fast Track designation facilitates enhanced communication with the FDA and prioritizes ARINA-1 for expedited development and review, underscoring Renovion’s dedication to improving respiratory health via patient-focused, groundbreaking treatments.
Bronchiolitis Obliterans Syndrome Market Industry Leaders And Market Competition
Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.
Access The Complete Bronchiolitis Obliterans Syndrome Market Report:
Bronchiolitis Obliterans Syndrome Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
